Resumen de acción SHILPAMED
Shilpa Medicare Limited, junto con sus filiales, se dedica a la fabricación y venta de ingredientes farmacéuticos activos (API), formulaciones farmacéuticas acabadas, productos biológicos y otros preparados farmacéuticos alopáticos en India, Estados Unidos, Europa y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de Shilpa Medicare Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹550.35 |
| 52 Week High | ₹561.60 |
| 52 Week Low | ₹228.50 |
| Beta | 0.78 |
| 1 Month Change | 11.20% |
| 3 Month Change | 46.47% |
| 1 Year Change | 112.70% |
| 3 Year Change | 24.54% |
| 5 Year Change | 44.75% |
| Change since IPO | 760.37% |
Noticias y actualizaciones recientes
What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You
Apr 12
Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up
Feb 21Recent updates
What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You
Apr 12Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up
Feb 21Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt
Jan 02These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively
Jul 17Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt
Mar 17Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)
Sep 22Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Sep 07Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Aug 14Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load
Jan 27Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why
Sep 21Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jun 17If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late
May 31Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 07Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year
Feb 20Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jan 26
Here's Why I Think Shilpa Medicare (NSE:SHILPAMED) Is An Interesting Stock
Jan 14Shilpa Medicare (NSE:SHILPAMED) Shareholders Have Enjoyed A 54% Share Price Gain
Jan 03Could The Shilpa Medicare Limited (NSE:SHILPAMED) Ownership Structure Tell Us Something Useful?
Dec 22Is There More To The Story Than Shilpa Medicare's (NSE:SHILPAMED) Earnings Growth?
Dec 11How Much Are Shilpa Medicare Limited (NSE:SHILPAMED) Insiders Taking Off The Table?
Nov 30How Is Shilpa Medicare's (NSE:SHILPAMED) CEO Compensated?
Nov 16Earnings Release: Here's Why Analysts Cut Their Shilpa Medicare Limited (NSE:SHILPAMED) Price Target To ₹611
Nov 04Could The Market Be Wrong About Shilpa Medicare Limited (NSE:SHILPAMED) Given Its Attractive Financial Prospects?
Oct 27Rentabilidad de los accionistas
| SHILPAMED | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | 3.6% | 1.8% | 1.6% |
| 1Y | 112.7% | 57.0% | 45.1% |
Rentabilidad vs. Industria: SHILPAMED superó al sector Indian Pharmaceuticals , que obtuvo un rendimiento del 56.7% el año pasado.
Rentabilidad vs. Mercado: SHILPAMED superó al mercado Indian, que obtuvo un rendimiento del 45% el año pasado.
Volatilidad de los precios
| SHILPAMED volatility | |
|---|---|
| SHILPAMED Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: El precio de las acciones de SHILPAMED ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de SHILPAMED (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1987 | 1,179 | Vishnukanth Bhutada | www.vbshilpa.com |
Shilpa Medicare Limited, junto con sus filiales, se dedica a la fabricación y venta de ingredientes farmacéuticos activos (API), formulaciones farmacéuticas acabadas, productos biológicos y otros preparados farmacéuticos alopáticos en India, Estados Unidos, Europa y a escala internacional. Entre sus principales API oncológicos se encuentran la capecitabina, el clorhidrato de gemcitabina, el pemetrexed, el axitinib, el clorhidrato de erlotinib y el clorhidrato de irinotecán; y API no oncológicos, como el ambroxol, el ácido tranexámico y el ácido ursodesoxicólico; así como nuevos sistemas de administración de fármacos. La empresa ofrece servicios de desarrollo y fabricación por contrato y formulaciones, como comprimidos, cápsulas, inyectables líquidos e inyectables liofilizados.
Resumen de fundamentos de Shilpa Medicare Limited
| Estadísticas fundamentales de SHILPAMED | |
|---|---|
| Capitalización bursátil | ₹47.80b |
| Beneficios(TTM) | -₹6.71m |
| Ingresos (TTM) | ₹11.25b |
4.2x
Ratio precio-ventas (PS)-7,127x
Ratio precio-beneficio (PE)¿Está SHILPAMED sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de SHILPAMED | |
|---|---|
| Ingresos | ₹11.25b |
| Coste de los ingresos | ₹4.44b |
| Beneficio bruto | ₹6.81b |
| Otros gastos | ₹6.81b |
| Beneficios | -₹6.71m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.077 |
| Margen bruto | 60.53% |
| Margen de beneficio neto | -0.06% |
| Ratio deuda/patrimonio | 48.8% |
¿Cómo se ha desempeñado SHILPAMED a largo plazo?
Ver rendimiento histórico y comparativa